Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected] ...

Early onset familial Alzheimer disease (eFAD) is hereditary and marked by Alzheimer disease symptoms that appear at an unusually early age. Symptoms can start in a person's thirties, forties, and ...

This database provides information about selected rodent models of neurodegenerative disease, including Alzheimer’s, Parkinson’s, and ALS. By summarizing, visualizing, and continuously updating ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Scientists from academia, pharmaceutical companies, and healthcare analysis firms reached no consensus on a threshold for meaningfulness, but broadly agreed that meaningfulness should be determined ...

As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...

In a Phase 2 trial, donanemab completely cleared plaque in two-thirds of participants. Their cognitive decline slowed by a third, meeting the primary endpoint. The treatment appeared to nudge down ...

Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid antibody Aduhelm ...

In a June 12 conference at UW-Madison, researchers gathered from across the U.S. and abroad to discuss the latest progress on TDP-43 biomarkers. In all, 74 people attended in person, and 727 virtually ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...